Format

Send to

Choose Destination
Clin Liver Dis. 2013 Feb;17(1):111-21. doi: 10.1016/j.cld.2012.09.006.

HCV NS5A inhibitors in development.

Author information

1
Division of Gastroenterology and Hepatology, University of Michigan Health System, University of Michigan, Ann Arbor, 48109, USA. aslok@umich.edu

Abstract

NS5A protein plays a key role in hepatitis C virus (HCV) replication. Daclatasvir (DCV, BMS-790052) is a first-in-class inhibitor of the HCV NS5A replication complex with potent antiviral activity but a low barrier to resistance. DCV as triple therapy in combination with pegylated interferon and ribavirin resulted in a high rate of early virologic response in treatment-naïve patients with genotype 1 infection; as quadruple therapy in combination with asunaprevir (BMS-650032, NS3 protease inhibitor), pegylated interferon, and ribavirin, it resulted in a high rate of sustained virologic response in genotype 1 prior null responders.

PMID:
23177287
DOI:
10.1016/j.cld.2012.09.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center